J. Kennedy

发表

Do adults change their lifestyle behaviors after a cancer diagnosis?

K. Courneya, D. Reding, M. Denniston, 2003, American journal of health behavior.

Some of the CANMAT Recommendations for the Pharmacological Treatment of Late-life Depression Are Not Congruent with Available Evidence or Expert Opinion

B. Pollock, B. Mulsant, M. Rapoport, 2017, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

Feasibility of Retrospective Assessments of Behavioral Symptoms in Alzheimer's Disease: A Preliminary Study of Postmortem Caregiver Reports

M. Strauss, J. Bolger, J. Kennedy, 1998, International Psychogeriatrics.

Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects

R. Salomon, E. Mignot, J. Zeitzer, 2003, Biological Psychiatry.

Long term use of neuroleptics by schizophrenic patients

J. T. Dalby, Richard J. Williams, J. Kennedy, 1991, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson's disease: A high potency effect of clozapine

H. Meltzer, D. Riley, J. Dai, 1995 .

Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease.

B. Pollock, D. W. Robin, J. Nelson, 1999, The American journal of psychiatry.

The rate, pattern, and cost of use of antiparkinsonian agents among patients treated for schizophrenia in a managed care setting.

H. Ascher-Svanum, J. Kennedy, David W. Lee, 2004, The American journal of managed care.

The Comparative Peripheral Anticholinergic-Like Adverse Event Profiles of Olanzapine and Risperidone.

F. Bymaster, B. Basson, P. Tran, 2000, The Primary Care Companion to the Journal Clinical Psychiatry.

Treatment of glossodynia with olanzapine.

F. Bymaster, G. Mirowski, J. Kennedy, 2004, Journal of the American Academy of Dermatology.

Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine.

F. Bymaster, J. Kennedy, M. Cohen, 2001, European journal of pharmacology.

Serial cerebrospinal fluid tryptophan and 5-hydroxy indoleacetic acid concentrations in healthy human subjects.

R. Shiavi, R. Salomon, Benjamin W. Johnson, 2002, Life sciences.

The effects of antipsychotic drug treatment on prolactin concentrations in elderly patients.

B. Kinon, R. Dickson, V. Stauffer, 2003, Journal of the American Medical Directors Association.

Personal history of depression and its appearance in Alzheimer's disease

M. Strauss, B. Carpenter, J. Kennedy, 1995 .

The influence of social support on depressive symptoms in cancer patients: age and gender differences.

D. Reding, M. Denniston, D. Hann, 2002, Journal of psychosomatic research.

Plasma Clozapine Levels and the Treatment of L-DOPA-Induced Psychosis in Parkinson's Disease

H. Meltzer, D. Riley, J. Dai, 1995, Neuropsychopharmacology.

Diagnosing Depression in Later Life

J. Ellison, J. M. Lawrence, D. Davidoff, 2008, Depression in Later Life.

Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States.

D. Hutchins, T. Hardy, K. Hornbuckle, 2004, Journal of the American Medical Directors Association.

Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans.

R. Polinsky, M. Ebert, A. Enz, 1999, Journal of clinical psychopharmacology.

Is absolute amount or change in exercise more associated with quality of life in adult cancer survivors?

K. Courneya, D. Reding, M. Denniston, 2003, Preventive medicine.

Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease.

B. Pollock, J. Bigger, J. Nelson, 1998, JAMA.

Validity of Self‐Reports of Caffeine Use

D. Greenblatt, J. Harmatz, L. Moltke, 1991, Journal of clinical pharmacology.

Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double‐blind controlled trial

Gerald Q. Maguire, D. Jeste, F. Bymaster, 2003, International journal of geriatric psychiatry.

The Use and Misuse of Psychotropic Prescribing for Elderly Psychiatric Patients

J. Kennedy, R. Ancill, G. Macewan, 1988, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

Pharmacotherapy of behavioral and psychological symptoms of dementia: a review of atypical antipsychotics.

L. Daiello, V. P. Hoffmann, M. Beier, 2003, The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists.

Factor Structure and Concurrent Validity of the Satisfaction with Life Domains Scale for Cancer (SLDS-C)

D. Reding, M. Denniston, D. Hann, 2007, Journal of psychosocial oncology.

Duloxetine for the treatment of major depressive disorder in older patients.

M. Detke, J. Nelson, C. Mallinckrodt, 2005, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

Effect of blood collection tubes on antidepressant concentrations.

D. Greenblatt, J. Harmatz, R. Shader, 1987, Journal of chromatography.

Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years.

G. Tollefson, A. Breier, P. Feldman, 2003, The Journal of clinical psychiatry.

Characterizing behavioral and psychological symptoms of dementia (BPSD) among geropsychiatric inpatients.

S. Tunis, W. Edell, J. Kennedy, 2002, Journal of the American Medical Directors Association.

Symptoms and diagnosis of depression in alcoholics.

R. Gibbons, J. Kennedy, W. Dorus, 1987, Alcoholism, clinical and experimental research.

Association of a Critical CSF Tryptophan Threshold Level with Depressive Relapse

R. Salomon, Benjamin W. Johnson, J. Kwentus, 2003, Neuropsychopharmacology.

The relationship of clinical psychopathologic rating and cognitive factors to clinical dementia staging

M. Strauss, P. Whitehouse, K. Smyth, 1993, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Superiority of olanzapine over risperidone in the control of negative symptoms of schizophrenia and related psychotic disorders in older patients

A. Breier, P. Feldman, V. Sutton, 2001, European Neuropsychopharmacology.

Treatment Enhances Ultradian Rhythms of CSF Monoamine Metabolites in Patients with Major Depressive Episodes

R. Shiavi, R. Salomon, Benjamin W. Johnson, 2005, Neuropsychopharmacology.

Lorazepam in the elderly—a retrospective study of the side-effects in 20 patients

J. Kennedy, R. Ancill, G. Macewan, 1987, Journal of psychopharmacology.